The American Society of Clinical Oncology has developed a system for grading the severity of cutaneous irAEs. This system provides appropriate guidelines for the treatment of cutaneous irAEs according to body surface area (BSA) involvement and additional manifestations. Cutaneous irAEs were classified based on histologic and clinical severity and percentage of BSA involvement (Brahmer JR et al. 2028).
Common Terminology Criteria for irAEs (immun-indizierte Adverse Events).CTCAE-Klassifikation;
DefinitionThis section has been translated automatically.
General informationThis section has been translated automatically.
Severity of cutaneous irAEs
- Asymptomatic with erythema/papules covering <10% of the KOF
- Erythema/papules covering 10 % to 30 % of the KOF can be both symptomatic and asymptomatic.
- Approximately >30% of the KOF is covered. The appearance of macules/papules with or without symptoms.
- Most severe skin reaction that can be life-threatening, such as SJS, TEN, affecting approximately >30% of KOF. Intensive medical care is required for appropriate treatment.
- KOF/BSA, body surface area.
- SJS, Stevens-Johnson syndrome.
- TEN, Toxic epidermal necrolysis.
LiteratureThis section has been translated automatically.
- Brahmer JR et al. (2028) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714-68).